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Dear Prof. Dr. med. Dr. phil. Johannes Ring 
 
 
  
We read with interest the guidelines recently published on sclerosing diseases of the 
skin (Part 2: Scleromyxedema, scleredema and nephrogenic systemic fibrosis)[1, 
2].   However, we are concerned that the guideline recommendations proposed for 
prevention of nephrogenic systemic fibrosis (NSF) are potentially dangerous. Although 
we recognise the challenges in constructing comprehensive guidelines, we are 
concerned that this may be because the guidelines have not involved a 
multidisciplinary team. 
  
If the guideline development process followed by a rigorous literature search and 
critical evaluation of evidence as in a GRADEing approach 
(http://www.gradeworkinggroup.org/ ) then the guideline may have focused on 
diagnosis and treatment rather than speculating on methods to prevent NSF (we note 
that the authors do not suggest how to prevent scleromyxedema or scleredema).  
  
It is striking the list of authors and affiliations contains neither radiologists nor any renal 
physicians - all authors are either dermatologists or rheumatologists.  Rheumatologists 
have become heavy users of imaging, however, usually less where gadolinium based 
contrast agent (GBCA) enhancement is vital, while dermatologists request little 
imaging. These groups may not fully understand the value of GBCA enhanced 
radiological investigations and appreciate the risks versus benefits. Most cases of NSF 
have been detected by nephrologists, as the patients attend for regular haemo- or 
peritoneal dialysis. 
  
The guideline document makes the simplistic assumption that administration of 
GBCAs in renal failure patients will almost certainly lead to NSF.  Clearly this is not 
the case, since even in a large cohort of end stage renal failure patients on dialysis in 
whom double and triple doses of gadodiamide (Omniscan, GE Healthcare – now 
considered a ‘high risk’ agent) were administered, only 3% developed clinically 
manifest NSF. Thus, the vast majority of approximately 97% did not develop NSF[3]. 
Hence there must be other risk factors for NSF that have yet to be ascertained.  For 
the cyclic chelate GBCAs (Dotarem, Gadovist & ProHance) there are virtually no 
unconfounded cases of NSF reported (and those published are controversial) while 
for gadobenate dimeglumine (MultiHance) there are none recorded[3, 4]. Furthermore, 
NSF itself is highly variable clinically, ranging from a rapidly progressive highly morbid 
systemic disease to isolated patches of skin thickening with little clinical import.  
  
Our main concern is that the guideline recommends the use of haemodialysis (HD) 
after GBCA exposure to prevent NSF.  The evidence for this is based on opinion rather 
than evidence. This is particularly true for the GBCAs used in Europe following 
the Committee for Medicinal Productsfor Human Use (CHMP) decision restricting use 
of linear gadolinium chelates. Indeed, there are risks in initiating HD in patients with 
no other indication for HD, such as those associated with central venous cannulation 
(haemorrhage, pneumothorax, infection) as well as the risk of HD itself.  This decision 
would be hard to defend given the lack of evidence, dubious postulated benefits 
(especially if ‘high-risk’ agents are not used) and associated risks of initiating HD[5].   
   
NSF is thankfully now, as far as we can tell, no longer a clinical concern.  The last 
published case in which this diagnosis was a patient who manifested skin thickening 
5.5 years following an exposure that occurred prior to the 2007 FDA warning (exposed 
to high dose Omniscan, now barred by the CHMP decision in Europe)[6, 7]. However, 
if a clinician suspects a new diagnosis of NSF, we suggest collaboration with a 
recognised expert in this field such as via the NSF registry (http://www.icnfdr.org).    
  
In summary, we are concerned that this document could influence inappropriate and 
potentially dangerous practice regarding avoidance of NSF and would urge the 
authors to urgently revisit these guidelines involving a multidisciplinary team including 
radiologists, nephrologists and dermatopathologists.  
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